You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
News and reporting on EGFR biomarkers.
AstraZeneca's EGFR-inhibitor has now demonstrated an 'overwhelming' disease-free survival and CNS recurrence benefit, but overall survival benefit remains unknown.
The MET inhibitor OMO-1 will be studied with Allist's EGFR inhibitor furmonertinib in patients with MET-positive, EGFR-mutated cancers.
NICE is reversing its earlier negative recommendation for the lung cancer drug after AstraZeneca agreed to provide it at a discount.
The final GioTag data suggests a survival benefit with the regimen among patients with EGFR-mutant NSCLC harboring acquired T790M resistance mutations.
However, the lack of biomarker-specific treatment data kept researchers from definitively concluding that precision oncology treatments were behind an accelerated rate of NSCLC mortality decline.
Outcomes from the US cohort of the GioTag study confirm the benefit of Tagrisso for NSCLC patients who have become resistant to first-line Gilotrif.
The companies will collaborate on a trial evaluating the HER3-targeted antibody drug conjugate patritumab deruxtecan in combiantion with AstraZeneca's Tagrisso.
The companies will work together to bring Guardant360 through regulatory approval and commercialize it as a CDx for Janssen's amivantamab.
The company will start Phase I/II trials to evaluate the safety and anti-tumor activity of its natural killer cells in combination with Herceptin or Erbitux in the third quarter of 2020.
The agency based its decision on a trial showing that patients receiving the combo had a median PFS of 19.4 months versus 12.4 months for those on Tarceva.